This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hemispherx Biopharma Licenses Alferon N Injection(R) To GP Pharm In Latin America

PHILADELPHIA, Dec. 20, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that the Company has entered into an agreement with GP Pharm Latinoamerica ("GP Pharm"), an affiliate company of Spanish GP Pharm SA ( www.gp-pharm.com ) for the marketing of Alferon N Injection®, the Company's natural interferon injection product which has been FDA approved for a category of sexually transmitted diseases in Argentina with an option for other Latin American countries upon receipt of those respective countries' regulatory approval for any use of the product. Under this Agreement, the Company will manufacture and supply Alferon N Injection® to GP Pharm in Argentina under an exclusive Sales, Marketing, Distribution and Supply Agreement.  Under this Agreement, GP Pharm will be responsible for gaining regulatory approval for each indication and commercializing Alferon N Injection® in Argentina. The Company has granted GP Pharm the right to expand its territory to include other Latin American countries based upon GP Pharm achieving regulatory approval and certain first sale performance milestones. 

Thomas Kenwood Equels, Executive Vice Chairman of Hemispherx and the leader of its world-wide marketing efforts, stated, "I am very pleased that we have broadened our relationship with GP Pharm to include Alferon N Injection®."

Mr. Braver of GP Pharm said, "We are also excited to have the opportunity to market the FDA approved product, Alferon N Injection®, a natural interferon with a proven track record of safety and historically demonstrated exceptional anti-viral capabilities, in Argentina and potentially throughout Latin America."

In June of 2010, the Company and GP Pharm entered into a similar Sales, Marketing, Distribution and Supply Agreement for regulatory approval and sale of Ampligen®, an experimental therapeutic, to treat Chronic Fatigue Syndrome ("CFS") for Argentina including the right to expand rights to sell this experimental therapeutic into other Latin American countries based upon GP Pharm's achieving regulatory approval and certain first sale performance milestones. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs